<cite id="uufuy"><noscript id="uufuy"></noscript></cite>
    <rp id="uufuy"></rp>

    A LONG-TERM FOCUS
    ON INNOVATION

    We welcome the opportunity to discuss:

    BUSINESS
    DEVELOPMENT
    COLLABORATIONS

    • In-licensing and / or R&D collaborations
      • Creative collaborations in emerging fields
      • Best-in-class technology platforms and capabilities to enhance the Regeneron antibody pipeline
    • Strategic late-stage development and commercial partnerships with other leading biopharma companies
    • Collaborations that maximize the global potential of our pipeline and ability to deliver new medicines to patients around the globe

    Introduce your assets or discuss
    late-stage partnership

    ACADEMIC &
    RESEARCH
    COLLABORATIONS

    • Non-Clinical Research Collaborations providing investigators from academic and research institutions access to our:

    Learn more

    • Clinical Collaborations / Investigator Initiated Studies (IIS) providing investigators and clinicians access to and / or funding for our:

    Learn more

    OUR BUSINESS DEVELOPMENT STRATEGY

    Our entrepreneurial culture and history as one of the industry’s longest-standing biotech companies fosters a high-science mindset, nimble decision-making and highly collaborative relationships.

    We follow the science, rather than limiting our innovations to any one therapeutic area. We are open to collaboration opportunities with the potential to offer important benefits to patients, representing a true scientific or medical advance. In particular, we consider:

    • Novel platforms that enable next-generation therapeutics
    • Technologies for antibody discovery and development against new / challenging targets
    • New approaches that enhance activity of tumor-directed antibodies
    • Biomarker discovery and validation
    • Drug delivery or formulation technologies that improve the efficacy / safety profile, address a CMC or supply challenge or enhance patient convenience or compliance
    • Studying the potential of combinations pairing our pipeline molecules with other innovative clinical-stage therapeutic candidates
    • Collaborations with leading academic groups to advance our efforts in human genetics, animal model development, target discovery, target validation and antibody discovery

    SOME OF OUR CURRENT COLLABORATORS INCLUDE:


    Bayer logo

    Global ophthalmology
    collaborations

    Sanofi logo

    Antibody and immunotherapy
    collaborations

    Icahn School of Medicine logo

    Antibody discovery
    agreement

    Columbia University logo

    Research collaboration on genetic
    basis of familial disease

    Teva logo

    Global collaboration for
    investigational pain therapeutic

    Intellia Therapeutics logo

    Gene-editing technology
    collaboration

    Adicet Bio logo

    Engineered immune cell
    therapeutics collaboration

    Alnylam logo

    RNA interference (RNAi)
    therapeutics collaboration

    免费四虎库精品视倾